Suggested remit: To appraise the clinical and cost effectiveness of talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatment lines including a proteasome inhibitor and lenalidomide.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6625
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6625:
- 16 July 2026 - 13 August 2026
Project Team
- Project lead
- scopingta@nice.org.uk
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 July 2026 | In progress. Scoping commencing |
| 18 August 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual